Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma - Wikidata - wikimedia - TriplyDB

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

http://www.wikidata.org/entity/Q34062033

about

Survival following reirradiation using intensity-modulated radiation therapy with temozolomide in selected patients with recurrent high grade gliomas The future of high-grade glioma: Where we are and where are we going.Phase II pilot study of single-agent etirinotecan pegol (NKTR-102) in bevacizumab-resistant high grade glioma.Predictive value of MGMT promoter methylation status in Asian and Caucasian patients with malignant gliomas: a meta-analysis Dose-dense temozolomide: is it still promising?Continuous Low-Dose Temozolomide Chemotherapy and Microvessel Density in Recurrent Glioblastoma.A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis†.Phase I/II Study of Temozolomide Plus Nimustine Chemotherapy for Recurrent Malignant Gliomas: Kyoto Neuro-oncology Group.Chemotherapy in glioma.The efficacy and safety of various dose-dense regimens of temozolomide for recurrent high-grade glioma: a systematic review with meta-analysis.Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial.Treatment options for recurrent high-grade gliomas.Management and treatment recommendations for World Health Organization Grade III and IV gliomas.Are we done with dose-intense temozolomide in recurrent glioblastoma?Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series.Analyses of repeated failures in cancer therapy for solid tumors: poor tumor-selective drug delivery, low therapeutic efficacy and unsustainable costs.

P2860

Q31033595-91A63450-2ABD-44D6-8556-490FAF4B8624 Q35114090-E1FA5924-F55E-4B0B-9AF8-6957E6931AC5 Q35675340-BF65B862-80A4-4CCC-BA07-967DF2CB8648 Q35679476-3F5C86D3-5554-4283-8597-00C551208EE4 Q35943654-1F0D1687-C905-4AAC-B1AE-A4E98284A3A8 Q36396360-21FF743D-9CB9-49B8-BEB3-8CCBBB42A504 Q37400326-E7CCB024-842D-4F9A-9C6C-519FBAAD6F9E Q37592456-E279B768-CE58-4A29-99C6-DA203115BCE3 Q38438439-787D073E-0D66-40BD-AF0E-DE00F069D4E7 Q38579564-172836B5-BC30-420B-9383-F33C7CA38ECC Q38726649-48C0AA25-9690-403F-8C25-5315BE15FD75 Q39045968-209237D8-2D8F-4D96-9181-052A8D5A414C Q41706326-86C1A292-0209-4E05-B3C4-087548D3BF63 Q42804587-C3ACEE45-723E-403D-8520-7E385C47A935 Q48149391-29280308-76A3-465C-AB78-91FE5627A166 Q51763013-C7DE6ECA-54AA-4653-A62F-61079037015E

P2860

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

http://www.wikidata.org/entity/Q34062033

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@ast

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@en

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@nl

type

label

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@ast

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@en

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@nl

prefLabel

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@ast

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@en

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@nl

P1433

Q34062033-4976C7E3-FDE2-4545-8C99-828B42AF218A

P1476

Q34062033-F4DAE8C5-1133-4E23-9D61-785D63C256B0

P2093

Q34062033-0D02E928-E207-46A4-A883-991B05FE5389

Q34062033-21AE7353-1474-465E-9B36-7CF5FD89D21A

Q34062033-29312CDA-560F-41B6-A192-83F9EF905FBD

Q34062033-32EB80AB-B9F4-463D-A19E-2289DDBF79B4

Q34062033-761D3280-5FAB-437B-834E-DEE54A98E2FD

Q34062033-852E84C1-2A80-443E-B994-41EC105494C9

Q34062033-D7A22AF9-1CEC-4B1B-9571-DCD60C9AD024

Q34062033-FC8D80B5-C202-42A7-BBAA-DC2A2A266132

P2860

Q34062033-036E2981-63C9-4C3C-8D05-8FEAB327539E

Q34062033-0A54F24C-67C9-4D16-B60D-5D25AEA0F94A

Q34062033-12CAD3C1-3429-4AC1-9F4D-244B87F4EF70

Q34062033-138F0E41-AE00-4168-A6DE-7E4051715A5A

Q34062033-1E831150-3B7B-4760-A254-BB8B79BE4C5D

Q34062033-217F1470-22DB-49C3-8B25-C7E9EFE60614

Q34062033-22941E2B-AC7B-4145-AA0E-5A0C3298C43D

Q34062033-277182D2-54E1-4A19-A564-C8EF950CC21C

Q34062033-2E34DBF0-D010-4806-85EE-17D3207B08B3

Q34062033-3F01EEEC-B4D8-454F-92B3-E4837D940FCD

P304

Q34062033-7F599BFA-FF4C-4E6E-8A35-F90626552097

P31

Q34062033-6A0943DA-0991-4EE3-AE6F-B3195DF211AF

P356

Q34062033-453A7BC9-8136-46F4-8501-04B798D4D16B

P433

Q34062033-C71ACD10-999A-4154-A822-A374526C3A1E

P478

Q34062033-1C5EFD50-F110-4E77-8559-6FAD7AE036FB

P50

Q34062033-6FD559E5-4F5B-4771-A6AA-E0520E980DAF

P577

Q34062033-0DF7010E-E41F-4D71-A5E1-28B5A953D62C

P698

Q34062033-6EBAAE36-56D5-4F39-B00D-816EFED1F76B

P921

Q34062033-09C433A9-8EFA-44E5-8DBC-8FC9F58BAFCA

P932

Q34062033-9B2D709A-61A6-4D06-BB44-DB66C517A5B2

P356

P1433

P1476

Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma

@en

P2093

Annette M Molinaro

http://www.w3.org/2001/XMLSchema#string

Ashley DeSilva

http://www.w3.org/2001/XMLSchema#string

Jennifer L Clarke

http://www.w3.org/2001/XMLSchema#string

Michael D Prados

http://www.w3.org/2001/XMLSchema#string

Mitchel S Berger

http://www.w3.org/2001/XMLSchema#string

Nicholas A Butowski

http://www.w3.org/2001/XMLSchema#string

Seunggu J Han

http://www.w3.org/2001/XMLSchema#string

Susan M Chang

http://www.w3.org/2001/XMLSchema#string

P2860

MGMT gene silencing and benefit from temozolomide in glioblastoma.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules

Dose-intensity temozolomide after concurrent chemoradiotherapy in operated high-grade gliomas.

Phase II study of two-weekly temozolomide in patients with high-grade gliomas.

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Randomized phase II trial of chemoradiotherapy followed by either dose-dense or metronomic temozolomide for newly diagnosed glioblastoma.

P304

1255-1262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NEUONC/NOU044

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

John D. Rolston

P577

2014-03-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24670608

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial

P932

4136897

http://www.w3.org/2001/XMLSchema#string